<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04755413</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001179</org_study_id>
    <nct_id>NCT04755413</nct_id>
  </id_info>
  <brief_title>The Precision CAD Trial</brief_title>
  <official_title>Use of Biomarker Risk Score to Optimize Therapy in Patients With Coronary Artery Disease: The Precision CAD Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      People with Coronary Artery Disease (CAD) have narrow or blocked arteries that supply blood&#xD;
      to the heart. Reduced blood flow to the heart muscle from CAD can cause chest pain or aching,&#xD;
      especially with exercise or activity. CAD can lead to weakening of the heart muscle or heart&#xD;
      failure, and a higher risk of heart attack or death. Certain proteins in the blood, known as&#xD;
      biomarkers, can be found in people with CAD. Higher levels of these biomarkers are associated&#xD;
      with a greater risk of complications from CAD. The purpose of this study is to see if a&#xD;
      customized treatment based on biomarkers will reduce the biomarker levels and lead to lower&#xD;
      risk of complications from CAD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      People with Coronary Artery Disease (CAD) have narrow or blocked arteries that supply blood&#xD;
      to the heart. Reduced blood flow to the heart muscle from CAD can cause chest pain or aching,&#xD;
      especially with exercise or activity. CAD can lead to weakening of the heart muscle or heart&#xD;
      failure, and a higher risk of heart attack or death. Certain proteins in the blood, known as&#xD;
      biomarkers, can be found in people with CAD. Higher levels of these biomarkers are associated&#xD;
      with a greater risk of complications from CAD. The purpose of this study is to see if a&#xD;
      customized treatment based on biomarkers will reduce the biomarker levels and lead to lower&#xD;
      risk of complications from CAD.&#xD;
&#xD;
      Participants with high biomarker levels will be randomly assigned (like flipping a coin) to&#xD;
      either the treatment group or usual care. Both groups will have physical exams, blood tests,&#xD;
      and answer questionnaires. Participants in the treatment group will have their medications&#xD;
      adjusted based on their biomarker levels. They will also be asked to make lifestyle changes&#xD;
      like diet, exercise, and quitting smoking. Participants in the usual care group will receive&#xD;
      the standard of care prescribed by their doctor.&#xD;
&#xD;
      This study will take place in research rooms at Emory University Hospital and the Woodruff&#xD;
      Memorial Research Building.&#xD;
&#xD;
      Participants will be paid for being in the study.&#xD;
&#xD;
      Participants will be recruited from Emory Healthcare outpatient cardiology clinics and cath&#xD;
      labs. Participants will be identified through the medical record and by their doctors.&#xD;
      Written consent will be obtained from Participants before they can join the study.&#xD;
&#xD;
      Study data and blood samples will be collected and banked for possible research in the&#xD;
      future. These may also be shared with other researchers including researchers outside of&#xD;
      Emory.&#xD;
&#xD;
      This study will advance scientific knowledge and benefit human health by giving us more&#xD;
      treatment options for CAD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma levels of hsCRP</measure>
    <time_frame>Baseline, 1 year post intervention</time_frame>
    <description>Blood will be drawn for measurement of plasma levels of hsCRP to compare the optimization group and the usual care group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma levels of hs-cTnI</measure>
    <time_frame>Baseline, 1 year post intervention</time_frame>
    <description>Blood will be drawn for measurement of plasma levels of hs-cTnI to compare the optimization group and the usual care group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma levels of BNP</measure>
    <time_frame>Baseline, 1 year post intervention</time_frame>
    <description>Blood will be drawn for measurement of plasma levels of BNP to compare the optimization group and the usual care group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma levels of suPAR</measure>
    <time_frame>Baseline, 1 year post intervention</time_frame>
    <description>Blood will be drawn for measurement of plasma levels of suPAR to compare the optimization group and the usual care group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Biomarker Risk Score (BRS)</measure>
    <time_frame>Baseline, 1 year post intervention</time_frame>
    <description>The BRS score is a simple and manual observation of 4 biomarker results above a predetermined cutpoint that are run on FDA cleared and or CE marked platforms. The BRS is calculated using levels of the 4 biomarkers. Biomarker levels will be considered abnormal if hsCRP is &gt;3 mg/L, suPAR (pg/mL) &gt;2863 (males) and &gt;4063 (women), hs-TnI (pg/mL)&gt; 6.3 (men), &gt;5.5 (women), and BNP (pg/mL) &gt;122 (men), &gt;184.1 (women). The BRS ranges from 0 to 4 based on the number of biomarkers that are elevated above these cut off values. Higher score correlates with worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in composite complications</measure>
    <time_frame>Baseline, 1,3,6,9 months post intervention and 1,2,3,5 years post intervention</time_frame>
    <description>Difference in rates of composite of CV death/MI/ heart failure hospitalizations, stroke/ revascularization between optimization group, usual care group and registry group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma levels of hsCRP</measure>
    <time_frame>Baseline, 1, 3, 6, 9 months post intervention and 2, 3, 5 years post intervention</time_frame>
    <description>Blood will be drawn for measurement of plasma levels of hsCRP to compare the optimization group and the usual care group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma levels of hs-cTnI</measure>
    <time_frame>Baseline, 1, 3, 6, 9 months post intervention and 2, 3, 5 years post intervention</time_frame>
    <description>Blood will be drawn for measurement of plasma levels of hs-cTnI to compare the optimization group and the usual care group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma levels of BNP</measure>
    <time_frame>Baseline, 1, 3, 6, 9 months post intervention and 2, 3, 5 years post intervention</time_frame>
    <description>Blood will be drawn for measurement of plasma levels of BNP to compare the optimization group and the usual care group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma levels of suPAR</measure>
    <time_frame>Baseline, 1, 3, 6, 9 months post intervention and 2, 3, 5 years post intervention</time_frame>
    <description>Blood will be drawn for measurement of plasma levels of suPAR to compare the optimization group and the usual care group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>5 years post intervention</time_frame>
    <description>All cause death at 5 years in the optimization group compared to usual care group.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Optimization Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CAD and a BRS greater than 0 who are randomized to the Optimization Group have treatment goals that include achieving LDL-C&lt;70 mg/dL, hemoglobin A1c &lt;7%, blood pressure &lt;130/80 mmHg, smoking cessation, at least 30 minutes of moderate-intensity aerobic activity 5 days a week and weight loss to body mass index &lt;30 kg/m2. To achieve these goals, both pharmacological and lifestyle interventions will be considered and individualized for each patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with CAD and a BRS greater than 0 who are randomized to the usual care group will receive standard of care therapy prescribed by their primary care physician and/or cardiologist. Patients and their physicians will be informed that their BRS is â‰¥1 and they have been randomized to the usual care group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Registry Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants with BRS of 0 at baseline and after 3 months will undergo follow-up including measurements of BRS at the time-points specified for the randomized subjects and also for adverse events. Laboratory results and questionnaire data will be obtained on the phone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical/Behavioral therapy</intervention_name>
    <description>Sedentary lifestyle: Advise increasing exercise to at least 30 minutes of moderate-intensity aerobic activity 5 days a week.&#xD;
Overweight/Obese: Advise calorie reduction, dietician consultation.&#xD;
Smoking: standard smoking cessation advice and literature and medical therapy as indicated to include Wellbutrin, nicotine patch etc.&#xD;
High LDL cholesterol: a) Start high dose statin if patient not on high dose statin.&#xD;
b) If on high dose statin, add ezetimibe 10mg daily c) If statin intolerant, start ezetimibe 10mg, colestid or other bile sequestrant combination.&#xD;
d) If still not at goal, start PCSK-9 inhibitor e) LDL cut off of &lt;55mg/dl in diabetes&#xD;
Blood Pressure optimization treatment following 2020 International Society of Hypertension Global Hypertension Practice Guidelines.&#xD;
Diabetes management: HbA1c goal 6.5%</description>
    <arm_group_label>Optimization Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Participants will receive standard of care therapy prescribed by their primary care physician and/or cardiologist.</description>
    <arm_group_label>Usual Care Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Registry</intervention_name>
    <description>Participants with BRS of 0 will get measurements of BRS at the time-points specified for the randomized subjects and also for adverse events.</description>
    <arm_group_label>Registry Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  individuals aged 21-90 years with stable CAD.&#xD;
&#xD;
          -  Patients with plaque at angiography exceeding &gt;50% in one or more coronary arteries at&#xD;
             any time will be eligible. Current obstructive CAD is not required for eligibility.&#xD;
&#xD;
          -  Patients undergoing revascularization therapy or recent acute coronary syndrome (ACS)&#xD;
             will be eligible for recruitment and will be recruited at least 4 weeks after&#xD;
             admission for an ACS or percutaneous intervention and 3 months after coronary bypass&#xD;
             graft surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  planned revascularization,&#xD;
&#xD;
          -  New York Heart Association class III or IV heart failure symptoms,&#xD;
&#xD;
          -  LVEF &lt;40%,&#xD;
&#xD;
          -  eGFR&lt;45,&#xD;
&#xD;
          -  pregnancy, congenital heart disease, severe symptomatic valvular heart disease, active&#xD;
             malignancy and cardiac transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arshed Quyyumi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joey Freshwater</last_name>
    <phone>404-712-6635</phone>
    <email>joey.freshwater@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory Johns Creek Hospiatl</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30097</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Joey Freshwater</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Joey Freshwater</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Joey Freshwater</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30324</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Joey Freshwater</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory Saint Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Joey Freshwater</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Arshed A. Quyyumi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

